Search clinical trials for: Neladenoson bialanate (BAY 1067197)

Total 6 results

Bayer

Terminated

Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose of 10 mg Immediate Release Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight

Pharmacology, Clinical

Germany
Bayer

Terminated

Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose in Participants With Liver Impairment and Healthy Participants Matched for Age-, Gender-, and Weight

Pharmacology, Clinical

Germany
Bayer

Completed

A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction (PANTHEON)

Heart Failure

United States, Israel, Spain, Poland, Japan, Italy, Belgium, Bulgaria, Germany, Greece, Netherlands
Bayer

Completed

A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction (PANACHE)

Heart Failure

United States, Spain, Israel, Belgium, Japan, Italy, Austria, Bulgaria, Germany, Greece, Poland, Portugal
Mayo Clinic
Astellas Pharma US, Inc.; University of Nebraska; Lantheus Medical Imaging

Completed

Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes (GLP-1)

Coronary Artery Disease | Diabetes Mellitus Type 2

United States
Cedars-Sinai Medical Center
National Institute for Biomedical Imaging and Bioengineering (NIBIB)

Completed

Contrast- Enhanced Whole-Heart Coronary MRA at 3.0T (Tesla)

Coronary Artery Disease

United States

3

Subscribe